KyungDong Pharm home
Prescription Medicines

KD Nicergoline Tab. 30mg (Nicergoline)

Product Category
Dementia and brain function improvement agent
Active Ingredients
Nicergoline
Appearance
A yellow, round, film-coated tablet.
Reimbursement Code
648105030
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet (215 milligrams)
- Active ingredient: Nicergoline (EP) · · · · · · · 30.0mg
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry yellow (03A620045), calcium hydrogen phosphate hydrate, low-substituted hydroxypropyl cellulose (LH-22), croscarmellose sodium

2. Effectiveness
* 5, 10mg
- Improvement of decreased motivation due to chronic cerebral circulation disorder accompanying cerebral infarction sequelae
- Arteriosclerotic headache in elderly people
- Adjunctive therapy for high blood pressure

* 30mg
Primary treatment of the following dementia syndromes related to primary degenerative vascular dementia and complex dementia: memory impairment, concentration impairment, judgment impairment, lack of proactiveness.

3. Dosage and dosage
* 5, 10mg
Adults: As nicergoline, take 5 to 10 mg orally 2 to 3 times a day before meals.
Increase or decrease appropriately depending on symptoms.

* 30mg
Adults: As nicergoline, take 30 mg orally once a day before meals. If the desired effect is not achieved at this dose, the dose can be increased up to 60 mg. It is possible to reduce the dose after symptoms improve.
For patients with kidney function abnormalities (serum creatinine >175 ?mol/L), the dose should be reduced (2 mg/dL).

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or ergot alkaloids
2) Patients with acute myocardial infarction
3) Patients with acute bleeding
4) Patients receiving sympathomimetic drugs
5) Patients with marked bradycardia (< 50 beats/min)
6) Patients who have not achieved hemostasis after intracranial hemorrhage
7) Patients with orthostatic control disorder

2. Administer with caution to the following patients.
1) Patients with mild bradycardia
2) Patients with renal dysfunction

3. Adverse reactions
1) Digestive system: In rare cases, loss of appetite, diarrhea, constipation, nausea, vomiting, scattered upper abdominal pain or cramps, dry mouth, etc. may occur.
2) Liver: Rarely, ALT and AST elevations may occur.
3) Circulatory system: In rare cases, dizziness, orthostatic dysfunction, high blood pressure, increased blood uric acid, and decreased blood pressure may occur.
4) Mental nervous system: In rare cases, drowsiness, fatigue, headache, tinnitus, fatigue, and insomnia may occur.
5) Hypersensitivity reaction: In rare cases, rash, hives, itching, flushing, or heat may occur.
6) As a result of conducting a use outcome survey for re-examination of this drug in 811 patients in Korea over 4 years after marketing, the number of adverse reactions that occurred was 30 cases (3.70%) in 22 patients. Among the adverse reactions that newly appeared after marketing, those that may have a causal relationship with this drug include nightmares, dysthymia, and indigestion (1 case each).

4. General precautions
1) If you use this drug together with other antihypertensive drugs, check your blood pressure frequently as the antihypertensive effect may increase.
2) Because it may affect the metabolism and excretion of uric acid, it should be administered with caution to patients with hyperuricemia or a past history of gout.
3) Be careful when driving or operating machinery after taking this medicine.

5. Interaction
1) This drug may increase the effect of antihypertensive drugs.
2) This drug is metabolized through CYP450 2D6, so interactions may occur with drugs that have the same metabolic pathway.

6. Administration to pregnant and lactating women
1) In animal experiments, there have been reports of causing embryotoxic malformations when administered in high doses.
2) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
3) Since secretion into breast milk has been reported in animal experiments, avoid administration during lactation and discontinue lactation if unavoidable circumstances arise.

7. Administration to elderly people
In general, elderly people have reduced physiological function, so they should be careful about reducing their intake.

8. Administration to children
Safety in children has not been established.

9. Treatment in case of overdose
Overdosage may temporarily lower blood pressure. If necessary, take necessary measures, such as measuring changes in blood pressure.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.

11. Pharmaceutical equivalence test information
A. The test drug Kyungdong Nicergoline Tablets 30 mg [KyungDong Pharm Co., Ltd.] and the reference drug Samion Tablets 30 mg (Nicergoline) [Ildong Pharmaceutical Co., Ltd.] were orally administered as a single dose on an empty stomach to healthy adults in a 2×2 cross-over study. As a result, the MDL (active metabolite of nicergoline) in the blood of 36 people was measured, and comparative evaluation values (AUCt, Cmax) were obtained. When log transformed and subjected to statistical processing, the 90% confidence interval of the geometric mean ratio was within 80.00 to 125.00%, proving biological equivalence.
※ Table: Refer to attached document

5. How to save
Light-proof sealed container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture